Page 72 - MemoriaCIBER2019-ENG

72
CIBER Annual report 2019
e-CATCH
Coordinator: Jordi Bruix Tudó
During 2019, there was a lack of activity on the platform with no consultations regarding patients made.
The platform has been maintained as an instrument to share images and documentation of studies led by resear- chers from the Liver Cancer group and also involving the participation of other CIBER groups in other locations.
By becoming an instrument for research in liver cancer studies, the decision was taken to redefine the platform ad- ding it as a research instrument of the Liver Cancer team and canceling the activity of providing second opinions and diagnostic / therapeutic advice.
Hepa-C
Coordinator: Xavier Forns Bernhardt
In 2019, a significant number of patients continued to be registered, although given the high cure rate, the analysis to be carried out will require prolonged follow-up with publications being delayed. Currently, a cohort of more than 12,000 patients is available, which constitutes high-value epidemiological material.
Registry of Vascular Liver Diseases. REHEVASC
Coordinator: Juan Carlos García Pagán
The REHEVASC platform has been running since September 20, 2011. It is a Registry of patients diagnosed with 4 Hepatic Vascular diseases in Spain of the type considered to be “Rare Diseases”, with a prevalence under 5/10,000 inhabitants. It covers diseases with non-cirrhotic portal hypertension (NCPH):
• Non-cirrhotic non-tumoural portal thrombosis (PVT). • Idiopathic portal hypertension (IPH).
• Budd-Chiari syndrome (BCS) .
• Congenital hepatic fibrosis (CHF).
Its main aim is to provide a “uniform” diagnosis and treatment for these diseases, as well as to improve their diag- nosis and treatment and to be able to carry out collaborative studies that allow furthering our knowledge of these diseases.
In 2019, new patients were diagnosed and registered in the following proportions:
• PVT: 35 patients, obtaining a final register of 374 pacientes in 2019 .
• IPH: 10 patients, obtaining a final register of 153 patients in 2019.
• BCS: 5 patients, obtaining a final register of 93 patients in 2019.
• CHF: No new patients have been diagnosed with a final register of 11 patients in 2019.